Site Search
Displaying results 321 - 330 of 391
Resource | Reviews and Snapshots,
This document gives a summary of HIV and AIDS related data in Malaysia for the year 2015.
Resource | Reviews and Snapshots,
In Malaysia, the key national planning process leads to the development of five-year national development plans, with the current 10th Malaysia Plan (10th MP) covering 2011–2015 and the 11th MP set to span 2016–2020.
As a result, the recent WHO–Malaysia Country Cooperation Strategy 2009–2013 was not aligned with the time frame of Malaysia’s primary development planning cycle. This is problematic as the country’s five-year planning cycle includes extensive consultations and processes that identify key national and sectoral priorities for the coming period. If the next CCS had been developed to cover 2014–2018, it would have continued to be out of step with this important national planning process.
This review, therefore, was undertaken with a view to considering the suitability of extending the framework described in the 2009–2013 CCS to also cover 2014–2015. This would then enable the next full CCS to cover 2016–2020, which would synchronize with the 11th MP.
Resource | Reviews and Snapshots,
Papua New Guinea is one of the twelve highest HIV burden countries in Asia and the Pacific region with an estimated 32,000 people living with HIV in 2013. There were an estimated 2,200 new HIV infections – a 31% decline since 2005. As of June 2014, 16,773 people were receiving antiretroviral therapy, and prevention of mother-to-child transmission coverage was 41% (35%-47%) in 2013.
Resource | Reviews and Snapshots,
Gender-based violence (GBV) is a fundamental violation of human rights. It is one of the worst manifestations of gender-based discrimination, disproportionately affecting girls and women. GBV is a global phenomenon that knows no geographical, cultural, social, economic, ethnic, or other boundaries. It occurs across all societies, and is a major obstacle to the achievement of gender equality.
The purpose of this review is to examine existing approaches in policy, programming and implementation responses to school-related gender-based violence (SRGBV) in the Asia-Pacific region. It seeks to advance our knowledge and learning in this field, both in terms of what we know about the phenomenon and its impact on individuals, as well as how best to address it, including through education.
Resource | Reviews and Snapshots,
By 2020, 90% of all people living with HIV will know their HIV status. By 2020, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy. By 2020, 90% of all people receiving antiretroviral therapy will have durable viral suppression. When these targets are achieved, at least 73% of all people living with HIV worldwide will be virally suppressed—a three-fold increase over current estimates of viral suppression. Modelling demonstrates that achieving these targets by 2020 will enable us to end the AIDS epidemic by 2030.
Resource | Reviews and Snapshots,
Recent progress towards zero discrimination in Asia and the Pacific: Punitive approaches to sex work, drug use and sexual relations between men; criminalization of HIV transmission; and enforcement of restrictions on entry, stay and residence against people living with HIV hinder access to HIV prevention and treatment services, and can contribute to the increase of HIV-related stigma and discrimination. Over the past years, over 10 countries in Asia and the Pacific have removed or revised a number of such punitive laws or policies. These actions are helping to enable more people to access HIV services.
Resource | Reviews and Snapshots,
The AIDS response has achieved astonishing successes in the leveraging of finances. In just over a decade, global financing for AIDS increased from millions to billions, reaching the highest levels ever in 2012 at US$ 19 billion. Asia and the Pacific have mirrored this global trend, with estimated regional HIV spending rising from US$ 700 million in 2005 to US$ 2.2 billion in 2012.
Resource | Reviews and Snapshots,
The AIDS response has achieved astonishing successes in the leveraging of finances. In just over a decade, global financing for AIDS increased from millions to billions, reaching highest levels ever in 2012 at US$ 19 billion. Asia and the Pacific has mirrored this global trend, with estimated regional HIV spending rising from US$ 700 million in 2005 to US$ 2.2 billion in 2012.
Resource | Reviews and Snapshots,
The Participatory Functional Review and Stock Take of Regional Networks Serving the Asia and the Pacific Region aims to understand the strategic contribution of 10 regional networks (selected by UNAIDS) over the past five years, further develop their institutional arrangements and capacities to deliver on their mandates, and strengthen their relevance and effectiveness especially their value-added to national stakeholders, donors, and the general public. As such the review provides the regional networks with an opportunity to take stock and determine how to better position themselves over the next 3 to 5 years in response to the changing landscape of HIV in the region and globally.
Resource | Reviews and Snapshots,
The report provides an overview of the patent landscape with respect to a select number of antiretroviral (ARV) medicines in developing countries as of April 2014. The focus is primarily on those ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
Part 1 provides a brief introduction to patents and licences and their effect on the market for ARVs. It introduces key concepts that will facilitate an understanding of the report. It also explains which data sources were used for the report and notes a number of disclaimers with regard to the information contained in the report.
Part 2 is the core of the report. It outlines the patent status and licensing status of each ARV in the 81 developing countries for which data are available. For each ARV the report indicates whether that ARV is included in fixed-dose combinations for which there may be patents. General conclusions are drawn in light of the data. The key purpose is to provide an overview of the patent landscape for each ARV and, in particular, to show in which countries market competition for a given ARV is possible in view of existing patents and licences.